| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 72.0 | 89.4 |
| Gross profit | 50.0 | 62.2 |
| Profit before tax | -17.8 | -2.7 |
| Net income | -17.5 | -2.3 |
| EPS (diluted, $ a share) | $-1.57 | $-0.21 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -19.4% |
|---|---|
| Gross margin | 69.5% |
| Operating margin | -26.9% |
10-Q filed with the SEC, NYSE: MED. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Medifast Inc: key numbers
- Share price
- $12.54Close, Nov 16
- Market cap
- $140M
- Shares outstanding
- 11.18MLatest SEC cover page
- Sector
- Manufacturing
- Industry
- Miscellaneous Food Preparations & Kindred ProductsSIC 2090
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Medifast Inc
All →Medifast Insider Parsa Kiai Buys $66.1K of Stock
Parsa Kiai bought 5,399 shares of Medifast Inc at $12.24 a share, worth $66.1K in total on Oct 28, 2026. Shares held after the trade: 712,891 (+0.8%).
- Value
- $66.1K
- Shares
- 5,399
- Price
- $12.24
- Holding change
- +0.8%
- Trade date
- Oct 28, 2026
Medifast Financial Results
Medifast reported Q3 2026 revenue of $72.0 million, a 19.4% decrease year-over-year, primarily due to a 47.7% decline in active earning coaches. The company posted a net loss of $17.5 million as it continues to execute its '3.0 strategy' focused on metabolic health and GLP-1 medication support. Management highlighted improved coach productivity and expects to return to profitability in the fourth quarter.
- Term
- Q3 2026
“The third quarter was about execution. With Trilivy now live, Reset Fuelings in our coaches’ hands, and our new compensation plan and Coach Hub launched, the major pieces of our 3.0 strategy are now in market. Revenue came in line with our guidance, and coach productivity improved year-over-year for the fourth consecutive quarter. Those are the kinds of indicators that have historically come before coach growth and revenue growth.”
Nick Johnson, Medifast's Chief Executive Officer
“The world is facing an unprecedented metabolic health crisis, and medication alone will not solve it. Lasting health requires lasting habits, and that is exactly what we were built to deliver. With nutritionally optimized products continually enhanced by research-backed ingredients that target metabolic health, and the proven power of coaching and our community, no one is better positioned to lead the way.”
Dr. Wayne Scott Andersen, Founder of the Mission, Independent Trilivy Coach
Medifast Insider Daniel R. Chard Sells $226K of Stock
Daniel R. Chard sold 19,089 shares of Medifast Inc at $11.73 to $11.98 a share (average $11.85) in 2 transactions, worth $226K in total between Sep 28, 2026 and Sep 29, 2026. Shares held after the trade: 130,609 (-6.8%).
- Value
- $226K
- Shares
- 19,089
- Average price
- $11.85
- Holding change
- -6.8%
- Trade date
- Sep 28, 2026 to Sep 29, 2026